TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (REVERSE study) has been completed. The study...
Last week TechnoPhage held its Annual Meeting where the CEO, Miguel Garcia, took the opportunity to speak to the collaborators about recent...
We are proud to announce that a potential new therapeutic antibody for the treatment of COVID-19 has been identified. The candidate antibody was...
Invest in our products
Learn more about GMP manufacturing
Who we are, What we do
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology